NeuroVesica was founded to make psychiatric treatment more precise.
Failed drug trials limit access to new treatments, and subjective measures in the clinic limit patient outcomes. NeuroVesica is driven to improve clinical trial success using our proprietary platform for predictive patient allocation, giving patients faster access to new treatment options. Our platform is positioned to provide accurate blood-based clinical diagnostic tools and novel ‘outside the box’ therapeutic target identification.
At NeuroVesica, we have the broadest longitudinal treatment-responsive EV dataset across psychiatric disorders to make the biggest impact in precision psychiatry.
NeuroVesica built a proprietary plataform comprised of objective EV proteomic changes across longitudinal and clinical trial datasets predictive of psychiatric diagnoses and treatment response.
Our transdiagnostic platform is the broadest longitudinal and treatment-responsive dataset across psychiatry that covers affective disorders, addiction, trauma exposure, and disorders of neurodevelopment.
We are currently building patient allocation partnerships for new clinical trials. For diagnostics and therapeutic target identification, we are in the preclinical stage.
Team
Tracy L. Bale, Ph.D.
Decades of expertise in neuroscience and the biology and function of EVs in preclinical and clinical outcomes.
Neill Epperson, M.D.
A psychiatrist with more than 30 years of translational neuroscience research and clinical trial expertise.
Arthur Feltrin, Ph.D.
Computational biologist integrating multi-omics and AI approaches to advance extracellular vesicle molecular signatures for precision psychiatry.
